A wrinkle is not where aging happens; it is where aging finally becomes visible.
For most of its modern history, aesthetic medicine has been a field defined by what the eye can see. Today, surgeons are no longer asking only what a face looks like. They are asking what kind of tissue is underneath.
Two patients of the same age, walking in with the same complaint, may have a “fundamentally different” biology, says Dr. Sarit Cohen, a board-certified plastic and aesthetic surgeon and head of the Center of Facial Sculpting. One may have skin that heals briskly and rebuilds itself easily, she says, while the other’s skin may be inflamed, slow to repair and low on the building blocks of regeneration. Both might look identical at the consultation, but only one will hold the result of the procedure for long. The surgery is identical, but the biology underneath is not.
Cohen describes a new direction in plastic surgery, a true shift in the field. “Ten or fifteen years ago, aesthetic assessment was centered primarily around visible anatomy, and the therapeutic paradigm was relatively straightforward across patients. If there was tissue descent, we performed a facelift. If there was volume loss, we restored volume.”
What she is pointing to is the merger of aesthetic medicine with longevity science, the broader research effort to understand and intervene in the biology of aging itself. “With aging, many cells stop functioning properly, lose their ability to repair tissue and begin releasing inflammatory signals that can contribute to chronic low-grade inflammation throughout the body,” explains Prof. Dominik Thor, president of the Geneva College of Longevity Science, the first higher-education institution dedicated to the field. “DNA stability declines, epigenetic information changes and alters gene activity, mitochondria, the energy producers of our cells, become less efficient, and proteins lose their proper structure and function, to name just a few of these processes.”
These are the hallmarks of aging. A canonical 2023 paper by López-Otín and colleagues lists 12 mechanisms linked to most of the chronic diseases that catch up to people in middle age and later. The skin happens to be the place where the slow process first shows. “Because it is visible, accessible, and measurable,” Thor says, “aesthetic medicine may become an important entry point into longevity medicine, helping to identify and address aging-related dysfunction earlier, while many processes may still be modifiable.”
This is an intriguing concept. Aesthetic medicine becomes a testing ground for new treatments, where outcomes are easily measured and observed, in the short term and the long term, bridging between theory and practice.
For anyone shopping for “longevity-grade” aesthetic care, Cohen has a practical test. “The first thing patients should look for is whether the conversation is biologic and mechanism-based—or purely cosmetic and procedure-based,” she says. “Does the practitioner explain why the tissue is aging biologically? Do they discuss tissue quality, inflammation, regenerative capacity, hormonal influences, lifestyle, vascularity, extracellular matrix integrity, or recovery dynamics? Or is the entire consultation focused only on visible defects and which device or injectable will be used?”
The science is real but the marketing is louder. Patients will struggle to tell them apart for some time. Clinicians who can will define what aesthetic longevity actually means. “Where longevity aesthetics becomes mostly vocabulary is when ‘longevity’ is simply used as a marketing label for premium cosmetics, injectables, or devices without a clear biological rationale, measurable outcomes, or meaningful long-term evidence,” says Thor.
The language of aesthetic medicine is changing, and the language usually comes first. The biology behind it is still on its way. Take skin-specific epigenetic clocks, the DNA-based tests being used to estimate a tissue’s biological age. They are still under research, while many consumer products invoking them are moving faster than the clinical data behind them. “Different clocks measure different aspects of aging; results can vary considerably, and we still lack sufficient long-term interventional and clinical data to support many of the claims currently used in cosmetic marketing,” Thor says.
The aesthetic longevity future is not here yet, but the convergence is genuine. “The field is promising, but we still need stronger biomarkers, better clinical validation, and more scientific rigor behind many of the claims currently being made,” Thor says.
“Beauty comes from within” used to be a platitude. Aesthetic longevity is slowly making it a clinical claim.
